12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Company News  |  Other News

Corning Inc., National Institutes of Health, Skoll Foundation, U.S. Agency for International Development (USAID), U.S. Centers for Disease Control and Preventio

FDA established a public-private partnership to develop its CD-3 device to identify counterfeit or substandard anti-malarial medicines. In 2013-14, U.S. Pharmacopeia, with funds from USAID and the multi-agency President's Malaria Initiative led by USAID and Skoll's Skoll Global Threats...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >